Bulk Pharmaceutical API Sources for cangrelor

Bulk Pharmaceutical API Sources for cangrelor

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		9854012
Chembase.cn		126374
AN PharmaTech		AN-37839
Acemol		AMMD00024

Cangrelor Bulk Active Pharmaceutical Ingredient Sources

Last updated: February 19, 2026

This report identifies current and potential bulk active pharmaceutical ingredient (API) sources for cangrelor, a direct P2Y12 receptor antagonist used as an antiplatelet agent. Key considerations include manufacturing capabilities, regulatory standing, and geographic distribution of API suppliers.

What is Cangrelor and its Market Significance?

Cangrelor is an intravenous antiplatelet medication administered to patients undergoing percutaneous coronary intervention (PCI). It prevents platelet aggregation by reversibly binding to the P2Y12 receptor on platelets. Its rapid onset and offset of action make it suitable for patients requiring immediate and short-term platelet inhibition during PCI.

The global market for antiplatelet drugs is substantial, driven by the increasing prevalence of cardiovascular diseases, particularly coronary artery disease and stroke. Cangrelor's unique pharmacokinetic profile positions it within the acute care segment of this market. Its primary application in PCI procedures underpins demand, with hospital settings being the main point of use. The market is subject to competition from oral P2Y12 inhibitors, but cangrelor's intravenous administration offers distinct advantages in specific clinical scenarios where rapid and titratable platelet inhibition is critical.

Who are the Key API Manufacturers for Cangrelor?

Identifying bulk API manufacturers for specialized drugs like cangrelor involves examining companies with expertise in complex organic synthesis and stringent Good Manufacturing Practice (GMP) compliance. Information on specific API suppliers for cangrelor is not always publicly disclosed by pharmaceutical companies due to proprietary reasons. However, analysis of patent filings, regulatory submissions, and industry databases can reveal potential or confirmed sources.

Established API Suppliers

Several Contract Development and Manufacturing Organizations (CDMOs) and specialized API manufacturers possess the technical capabilities to produce complex small molecules like cangrelor. These companies often serve multiple pharmaceutical clients and operate under strict regulatory oversight.

• Companies with relevant synthetic chemistry expertise and GMP facilities. While specific cangrelor manufacturers are not widely published, companies with demonstrated capabilities in producing small molecule APIs for cardiovascular indications or other complex therapeutic areas are likely candidates. These include:
  • Lonza Group AG: A global CDMO with extensive experience in small molecule API manufacturing, including complex chiral syntheses and high-potency APIs. Lonza operates manufacturing sites across Europe and North America.
  • Catalent, Inc.: Another major CDMO offering integrated drug substance development and manufacturing services. Catalent has a broad global footprint and expertise in various chemical synthesis technologies.
  • Dr. Reddy's Laboratories: An Indian multinational pharmaceutical company with a significant API manufacturing division. They have a strong presence in producing APIs for various therapeutic classes, adhering to international regulatory standards.
  • Divi's Laboratories: An Indian API manufacturer known for its large-scale production capabilities and strong regulatory compliance, particularly in complex chemical synthesis.
  • AbbVie Inc. (formerly Allergan): While primarily a finished dosage form producer, AbbVie has internal manufacturing capabilities for APIs and may produce critical intermediates or APIs for its product portfolio.

Potential New Entrants and Regional Hubs

The geographic distribution of API manufacturing is increasingly diversified, with a growing presence of manufacturers in Asia. Companies in China and India are significant players in the global API market due to their manufacturing scale and cost-effectiveness, while also meeting stringent quality standards.

• China: A major hub for API production globally. Numerous Chinese chemical and pharmaceutical companies possess advanced synthesis capabilities and operate under GMP guidelines mandated by regulatory bodies like the NMPA (National Medical Products Administration) and international agencies. Examples of large API producers with broad portfolios include:

  • WuXi AppTec: A leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company. They offer end-to-end R&D and manufacturing services, including API development and production.
  • Pharmasoo (China): A supplier of pharmaceutical raw materials and intermediates, often catering to global markets.

• India: India is a powerhouse in generic drug manufacturing and API production. Many Indian companies are established suppliers to regulated markets in the US and Europe.

  • Aurobindo Pharma Limited: A vertically integrated pharmaceutical company with significant API manufacturing capacity.
  • Laurus Labs Limited: Specializes in APIs for various therapeutic areas, including cardiovascular.

What are the Regulatory Requirements for Cangrelor API?

The manufacturing of bulk APIs for pharmaceutical use, including cangrelor, is subject to rigorous regulatory oversight by health authorities worldwide. Compliance with current Good Manufacturing Practices (cGMP) is paramount.

Key Regulatory Bodies and Standards

• U.S. Food and Drug Administration (FDA): Regulates API manufacturing in the United States. Manufacturers must adhere to 21 CFR Part 210 and 211.
• European Medicines Agency (EMA): Oversees API manufacturing for the European Union. Compliance with EudraLex Volume 4 is mandatory.
• Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
• National Medical Products Administration (NMPA) in China.
• Central Drugs Standard Control Organization (CDSCO) in India.

Common Regulatory Filings and Inspections

• Drug Master File (DMF): API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Pharmaceutical companies reference these DMFs in their drug product applications (e.g., New Drug Applications - NDAs, Abbreviated New Drug Applications - ANDAs).
• Inspections: Regulatory agencies conduct routine and pre-approval inspections of API manufacturing facilities to ensure compliance with cGMP. Successful inspections are critical for API sourcing.
• Quality Agreements: Pharmaceutical companies establish detailed quality agreements with their API suppliers to define responsibilities and ensure consistent product quality.

What are the Manufacturing Challenges and Considerations for Cangrelor API?

The synthesis of cangrelor presents specific chemical challenges that influence API sourcing decisions. Cangrelor is a synthetic molecule with a distinct chemical structure, requiring multi-step synthesis.

Chemical Synthesis and Purity

• Stereochemistry: Cangrelor has chiral centers, necessitating stereoselective synthesis routes to ensure the production of the correct enantiomer, which is crucial for pharmacological activity and safety. Control of stereochemical purity is a critical quality attribute.
• Impurity Profile: Managing and controlling process-related impurities, degradation products, and residual solvents is essential. Robust analytical methods are required to detect and quantify these impurities at very low levels. Regulatory agencies set strict limits for impurities.
• Scale-Up: Transitioning from laboratory-scale synthesis to large-scale commercial manufacturing requires optimization of reaction conditions, process safety assessment, and validation of the scaled-up process.
• Raw Material Sourcing: Secure and reliable sourcing of key starting materials and intermediates is vital. Manufacturers must qualify their raw material suppliers to ensure consistent quality.

Supply Chain Risks

• Geopolitical Stability: Concentration of API manufacturing in specific geographic regions can expose the supply chain to geopolitical risks, trade disputes, and natural disasters.
• Intellectual Property (IP): While the innovator's patent protection for cangrelor (Kengreal/Kengixx) will eventually expire, current manufacturing processes may be covered by process patents. Generic API manufacturers must ensure their synthesis routes do not infringe on existing IP. The innovator's patent for cangrelor is US Patent 8,058,278 B2, expiring in 2027. However, process patents can extend protection.
• Capacity and Lead Times: Ensuring sufficient manufacturing capacity and managing lead times are crucial to meet market demand and avoid drug shortages.

Who are the Potential End-Users of Cangrelor API?

The primary end-users of bulk cangrelor API are pharmaceutical companies that formulate and market the finished drug product.

Innovator and Generic Companies

• Innovator Company: The originator of cangrelor, currently marketed by The Medicines Company (a division of Novartis), is the primary user of its proprietary manufacturing process and API sources.
• Generic Manufacturers: As patents expire or through licensing agreements, generic pharmaceutical companies will seek to develop and market their own cangrelor products. These companies will require access to GMP-compliant cangrelor API from qualified suppliers. The development of generic cangrelor products is contingent upon patent expiry and regulatory approval.

What is the Current Status of Cangrelor API Sourcing?

Current sourcing for the innovator product is proprietary. However, the landscape for generic API sourcing will evolve as patents mature.

Innovator Supply Chain

The Medicines Company (Novartis) likely relies on a combination of internal manufacturing and contracted CDMOs for its cangrelor API. The specific suppliers are not publicly disclosed.

Generic Market Outlook

The development of generic cangrelor is anticipated following patent expiry. Companies exploring generic entry will need to:

1. Identify and qualify API manufacturers with robust cGMP compliance and capabilities in complex small molecule synthesis.
2. Develop non-infringing manufacturing processes.
3. Secure regulatory approvals for their API and finished drug product.

Companies that have invested in advanced synthetic capabilities and have a strong regulatory track record are well-positioned to enter this market.

Key Takeaways

• Cangrelor API manufacturing requires specialized expertise in complex organic synthesis, stereochemical control, and stringent cGMP compliance.
• Established global CDMOs and API manufacturers in North America, Europe, India, and China are the primary potential suppliers.
• Regulatory adherence to FDA, EMA, and other national health authority guidelines, including DMF filing and site inspections, is critical.
• Supply chain risks include geopolitical factors, intellectual property considerations, and manufacturing capacity constraints.
• Generic manufacturers will be the primary new demand drivers for cangrelor API as innovator patents expire.

FAQs

1. What are the primary therapeutic areas where cangrelor API is utilized? Cangrelor API is utilized for the production of antiplatelet drugs primarily indicated for patients undergoing percutaneous coronary intervention (PCI) to prevent thrombotic events.

2. Which regulatory bodies have the most significant influence on cangrelor API sourcing? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have the most significant influence on cangrelor API sourcing for major global markets. Other national regulatory bodies, such as China's NMPA and India's CDSCO, are also critical depending on the target market.

3. What are the key challenges in the chemical synthesis of cangrelor API? Key challenges include achieving high stereochemical purity due to chiral centers, controlling and minimizing impurities, and successfully scaling up the multi-step synthesis process from laboratory to commercial volumes.

4. How does intellectual property affect the sourcing of cangrelor API? Innovator patent protection on the drug substance and specific manufacturing processes can restrict sourcing options until these patents expire. Generic API manufacturers must develop non-infringing processes, which can influence the selection of API suppliers and their synthetic routes.

5. What are the typical lead times for sourcing bulk cangrelor API from a new supplier? Lead times for sourcing bulk API from a new supplier can range from 6 to 18 months, depending on the supplier's existing capacity, the complexity of the manufacturing process, the need for process validation, and regulatory approval timelines for facility inspections and drug master file reviews.

Citations

[1] U.S. Food & Drug Administration. (n.d.). 21 CFR Part 210: Current Good Manufacturing Practice in Manufacturing, Processing, Packaging, or Holding of Drugs; General. U.S. Government Publishing Office. [2] European Medicines Agency. (n.d.). EudraLex Volume 4: Good manufacturing practice (GMP) guidelines. European Union. [3] U.S. Patent 8,058,278 B2. (2012). Disclosed pharmaceutical compositions comprising cangrelor. [4] WuXi AppTec. (n.d.). API Services. Retrieved from https://www.wuxiapptec.com/service-offerings/small-molecule-drug-substance-manufacturing/ [5] Lonza Group AG. (n.d.). Small Molecules. Retrieved from https://www.lonza.com/products-and-services/biologics-and-chemical-manufacturing/small-molecules [6] Catalent, Inc. (n.d.). Drug Substance Development & Manufacturing. Retrieved from https://www.catalent.com/services/drug-substance-development-and-manufacturing/